Видео 34
Просмотров 17 681

57:56

Belantamab Makes a Comeback with Dr. Hang Quach

44:23

Management of Older Adults with Hodgkin Lymphoma with Dr. Andrew Evens

42:09

Quadruplets in Newly Diagnosed Transplant-Ineligible Myeloma

41:15

Updates in Low Risk MDS with Dr. Max Stahl

53:23

Management of Polycythemia Vera with Dr. Aaron Gerds

56:45

ASH 2024 Myeloma Update with Dr. Rakesh Popat

In this episode, we dive into the hottest updates in myeloma and amyloidosis at ASH 2024 annual meeting with Dr. Rakesh Popat. Here are the abstracts we discussed:
1. AQUILA Trial in High-Risk SMM
Overview of the AQUILA trial testing single-agent daratumumab for high-risk smoldering multiple myeloma (HR-SMM) versus active monitoring.
Discussion on patient characteristics, primary endpoints, and results showing significant progression-free survival (PFS) benefit with Dara.
Insights into modes of progression and the adequacy of active surveillance.
Read the abstract: ash.confex.com/ash/2024/webprogram/Paper201057.html
Read the simultaneous publication at NEJM: www.nejm.org/
2. Anito-Cel: New BCMA...

Видео

57:56

ASH 2024 Lymphoma and CLL Highlights

Просмотров 442Месяц назад

In this episode, we discussed the top abstracts in lymphoma and CLL presented at the ASH 2024 annual meeting in San Diego with Dr. David A Russler-Germain from Washington University. Here are the key abstracts we discussed: 1. 3 RCTs in Mantle Cell Lymphoma: a) Update on TRIANGLE: ash.confex.com/ash/2024/webprogram/Paper200735.html b) ENRICT Trial (Continuous Ibrutinib-Rituximab vs CIT [R-CHOP ...

Belantamab Makes a Comeback with Dr. Hang Quach

44:23

Belantamab Makes a Comeback with Dr. Hang Quach

Просмотров 1142 месяца назад

In this episode, we discuss the comeback of belantamab mafadotin in multiple myeloma with Dr. Hang Quach, along with some other important abstracts presented at EHA/ASCO 2024. Here are the studies we discussed: 1. DREAMM-7 RCT: Belantamab-Vd vs Daratumumab-Vd in relapsed MM. pubmed.ncbi.nlm.nih.gov/38828933/ 2. DREAMM-8 RCT: Belantamab-Pd vs PVd in relapsed MM. pubmed.ncbi.nlm.nih.gov/38828951/...

Management of Older Adults with Hodgkin Lymphoma with Dr. Andrew Evens

42:09

Management of Older Adults with Hodgkin Lymphoma with Dr. Andrew Evens

Просмотров 932 месяца назад

In this episode, we dive into the management of older adults with Hodgkin Lymphoma with Dr. Andrew Evens. Here are the key articles we discussed: 1. Comparison of ABVD versus Stanford V in older Hodgkin Lymphoma patients: pmc.ncbi.nlm.nih.gov/articles/PMC3906856/ 2. Outcome of older adults ECHELON-1: pubmed.ncbi.nlm.nih.gov/34162178/ 3. Sequential BV-AVD in older adults with Hodgkin Lymphoma: p...

Quadruplets in Newly Diagnosed Transplant-Ineligible Myeloma

41:15

Quadruplets in Newly Diagnosed Transplant-Ineligible Myeloma

Просмотров 1824 месяца назад

In this episode, we discuss the management of newly diagnosed transplant in-eligible multiple myeloma with Dr. Timothy Schmidt, with a special focus on IMROZ and BENEFIT RCTs testing quadruplets in this space. Here are the key papers we discussed: 1. MAIA trial (Daratumumab-Lenalidomide-Dexamethasone [DRd] vs Rd in newly diagnosed transplant ineligible myeloma): pubmed.ncbi.nlm.nih.gov/34655533...

Updates in Low Risk MDS with Dr. Max Stahl

53:23

Updates in Low Risk MDS with Dr. Max Stahl

Просмотров 1865 месяцев назад

In this episode, we discuss updates on low-risk MDS with Dr. Maximilian Stahl with a focus on imetelstat and luspatercept. Here are the trials we discussed: 1. IWG 2019 response criteria www.ncbi.nlm.nih.gov/pmc/articles/PMC7042664/ 2. MEDALIST trial: Luspatercept www.nejm.org/doi/10.1056/NEJMoa1908892?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub 0pubmed 3. COMMANDS trial : Lu...

Management of Polycythemia Vera with Dr. Aaron Gerds

56:45

Management of Polycythemia Vera with Dr. Aaron Gerds

Просмотров 2,2 тыс.6 месяцев назад

In this episode, we discussed the diagnosis and management of polycythemia vera with Dr. Aaron T. Gerds. Here are the shownotes with the key studies discussed: 1. MIPS PV scoring system pubmed.ncbi.nlm.nih.gov/31945802/ 2. REVEAL study ashpublications.org/blood/article/143/16/1646/506717/Association-between-elevated-white-blood-cell 3. MAJIC PV study ascopubs.org/doi/10.1200/JCO.22.01935?url_ve...

ASCO/EHA 2024 Lymphoma Updates with Dr. Gloria Iacoboni

47:25

ASCO/EHA 2024 Lymphoma Updates with Dr. Gloria Iacoboni

Просмотров 5636 месяцев назад

In this episode, we reviewed the hottest updates in lymphoma from ASCO and EHA 2024, held in Chicago and Madrid respectively, with Dr. Gloria Iacoboni, a haematologist from University Hospital Vall d'Hebron, in Barcelona, Spain. Here are the key abstracts we discussed: 1. STARGLO: Glofit-GEMOX vs R-GEMOX in relapsed/refractory DLBCL library.ehaweb.org/eha/2024/eha2024-congress/4136516 2. Epco-P...

Updates in Primary Myelofibrosis with Dr. Ayalew Tefferi

1:00:28

Updates in Primary Myelofibrosis with Dr. Ayalew Tefferi

Просмотров 6127 месяцев назад

In this episode, we discuss updates in primary myelofibrosis with Dr. Ayalew Tefferi from the Mayo Clinic. Here are the key studies we discussed: 1. GIPSS: Genetically inspired prognostic scoring system that is exclusively based on genetic markers. www.nature.com/articles/s41375-018-0107-z 2. MIPSS70 Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primar...

Maintenance Therapy in Myeloma with Dr. Hira Mian and Dr. Manni Mohyuddin

52:35

Maintenance Therapy in Myeloma with Dr. Hira Mian and Dr. Manni Mohyuddin

Просмотров 7038 месяцев назад

In this episode, we dive into the data on maintenance therapy in multiple myeloma with Dr. Hira Mian and Dr. Manni Mohyuddin. Here are the key studies we discussed: 1. Meta-analysis of individual patient-level data from CALGB, IFM, and Italian maintenance RCTs (lenalidomide vs placebo or observation): pubmed.ncbi.nlm.nih.gov/28742454/ 2. Myeloma XI RCT (lenalidomide vs observation): pubmed.ncbi...

Essential Thrombocythemia with Dr. Raajit Rampal

35:08

Essential Thrombocythemia with Dr. Raajit Rampal

Просмотров 2,4 тыс.9 месяцев назад

In this episode, we discuss the diagnosis and management of Essential Thrombocythemia with Dr. Raajit Rampal. Here are the shownotes: 1. IPSET (revised) system, risk categories are defined by the presence of a prior thrombosis, age, and JAK2 mutation status: ashpublications.org/blood/article/120/26/5128/30914/Development-and-validation-of-an-International 2. The MIPSS-ET provides points for: · ...

Career Development as a Clinician-Investigator with Dr. Ayalew Tefferi

47:00

Career Development as a Clinician-Investigator with Dr. Ayalew Tefferi

Просмотров 1429 месяцев назад

In this episode, we discuss mentorship and career development as a clinician-investigator with Dr. Ayalew Tefferi from the Mayo Clinic.

47:00

Career Development as a Clinician-Investigator with Dr. Ayalew Tefferi

Просмотров 14110 месяцев назад

In this episode, we discuss mentorship and career development as a clinician-investigator with Dr. Ayalew Tefferi from the Mayo Clinic.

Management of Newly Diagnosed AL Amyloidosis

50:18

Management of Newly Diagnosed AL Amyloidosis

Просмотров 29111 месяцев назад

In this episode we discuss the management of newly diagnosed AL amyloidosis with Dr. Angela Dispenzieri from the Mayo Clinic. Here are the key articles discussed: 1. Optimal use of tissue biopsy in AL amyloidosis: pubmed.ncbi.nlm.nih.gov/28271734/ 2. Mayo 2004 staging: pubmed.ncbi.nlm.nih.gov/15365071/ 3. Mayo 2012 staging: www.ncbi.nlm.nih.gov/pmc/articles/PMC3675680/ 4. Renal staging: pubmed....

ASH 2023 Leukemia and Myeloid Neoplasm Recap with Dr. Anand Patel

54:51

ASH 2023 Leukemia and Myeloid Neoplasm Recap with Dr. Anand Patel

Просмотров 14511 месяцев назад

In this episode, we discuss top abstracts in the myeloid space from the American Society of Hematology 2023 meeting with Dr. Anand Patel. Here are the abstracts that were discussed: 1. TRANSFORM-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelo...